论文部分内容阅读
The combination of doxorubicin (DOX) with sorafenib (SOR) has been proved to be an effective strategy to enhance anti-hepatocellular carcinoma (HCC) efficiency However, varied in vivo pharmacokinetic profiles and different endocytosis capacities of these two drugs greatly hinder their current application.